



(51) International Patent Classification:

C07D 207/36 (2006.01) C07D 413/04 (2006.01)
C07D 417/04 (2006.01) A61K 31/402 (2006.01)
C07D 401/04 (2006.01) A61K 31/4245 (2006.01)
C07D 401/12 (2006.01) A61K 31/427 (2006.01)
C07D 403/04 (2006.01) A61K 31/4439 (2006.01)
C07D 407/04 (2006.01) A61P 31/04 (2006.01)

(21) International Application Number:

PCT/GB2012/053022

(22) International Filing Date:

5 December 2012 (05.12.2012)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

11191986.6 5 December 2011 (05.12.2011) EP

(71) Applicant: UNIVERSITY OF LEICESTER [GB/GB];
Fielding Johnson Building, University Road, Leicester LE1
7RH (GB).

(72) Inventors: ANDREW, Peter William; University of
Leicester, Department of Infection Immunity and Inflam-
mation, Medical Sciences Building, University Road,
Leicester LE1 7RH (GB). LONNEN, Rana; University of
Leicester, Department of Infection Immunity and Inflam-
mation, Medical Sciences Building, University Road,
Leicester LE1 7RH (GB). DAMASO, Mafalda Pires; Uni-
versity of Leicester, Department of Infection Immunity and
Inflammation, Medical Sciences Building, University
Road, Leicester LE1 7RH (GB). FRICKEL, Fritz-
Frieder; Silvanerweg 7, 67146 Deidesheim (DE). HIRST,
Simon Christopher; Sygnature Discovery, BioCity,
Pennyfoot Street, Nottingham NG1 1GF (GB). DAVIES,
Mark William; Sygnature Discovery, BioCity, Pennyfoot
Street, Nottingham NG1 1GF (GB). HAMZA, Daniel;
Sygnature Discovery, BioCity, Pennyfoot Street, Notting-
ham NG1 1GF (GB).


(74) Agents: TEUTEN, Andrew et al.; Sagittarius IP, Three
Globeside, Fieldhouse Lane, Marlow, Buckinghamshire
SL7 1HZ (GB).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY,
BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP,
KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD,
ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI,
NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU,
RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ,
TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA,
ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ,
UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,
TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,

[Continued on next page]

(54) Title: NOVEL PYRROLE DERIVATIVES



(57) Abstract: There are provided inter alia compounds of formula (I) wherein R¹, R², R³, R^{4a} and R^{4b} are as defined in the specifica-
tion and their use in therapy, especially in the treatment of bacterial (e.g. pneumococcal) infections.



EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU,
LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK,
SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ,
GW, ML, MR, NE, SN, TD, TG).

— *before the expiration of the time limit for amending the
claims and to be republished in the event of receipt of
amendments (Rule 48.2(h))*

Published:

— *with international search report (Art. 21(3))*

(88) Date of publication of the international search report:

8 August 2013